Atara biotherapeutics appoints cell therapy and oncology commercialization veteran ameet mallik to the board of directors

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the appointment of ameet mallik to the board of directors. mr. mallik is a biotechnology and pharmaceutical industry expert with a successful track record of bringing innovative oncology therapeutics, including car t cell
ATRA Ratings Summary
ATRA Quant Ranking